CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for targeted therapy in previously untreated patients with KRAS-mutant NSCLC in the context of current standard of care with chemoimmunotherapy; Interpret the clinical evidence for emerging KRAS inhibitors in patients with previously untreated NSCLC; and Propose how emerging KRAS inhibitors may fit into the treatment paradigm for treatment-naive patients with KRAS-mutant NSCLC.

Please visit answersincme.com/NZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sebastien J. Hotte, MD, FRCPC. In this activity, an expert in oncology discusses radioligand therapy for metastatic castration-resistant prostate cancer. Upon completion of this activity, participants should be better able to: Evaluate how the current guidelines and evidence may inform the sequencing of radioligand therapies in patients with metastatic castration-resistant prostate cancer (mCRPC); Apply evidence-based approaches to optimally sequence radioligand therapies in patients with mCRPC; and Identify strategies to optimize bone health management in patients with mCRPC.

Please visit answersincme.com/860/102653681-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus Berdeja, MD; and Saad Z. Usmani, MD, MBA, FACP, FASCO. In this activity, experts in multiple myeloma (MM) discuss how BCMA bispecific antibody (BsAb)–anti-CD38 monoclonal antibody combinations fit into the treatment paradigm for patients with relapsed/refractory MM. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BCMA BsAbs in combination with anti-CD38 antibodies in the treatment of patients with RRMM; Review the clinical implications of the latest efficacy and safety data for BCMA BsAbs in combination with anti-CD38 antibodies in patients with RRMM; Outline potential considerations for integrating BCMA BsAbs in combination with anti-CD38 antibodies, as they become available, into the treatment of patients with RRMM, in the community setting; and Apply practical tools for optimizing the use of BCMA BsAbs in the community setting.

Please visit answersincme.com/AXB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Bijal Shah, MD, MS. In this activity, an expert in oncology discusses B-cell acute lymphoblastic leukemia. Upon completion of this activity, participants should be better able to: Describe the rationale for the development of novel dual CD19 x CD3-targeting bispecific antibodies for patients with relapsed/refractory; B-cell acute lymphoblastic leukemia (R/R B-ALL); Discuss the safety profiles of available and emerging CD19 x CD3-targeting bispecific antibodies; and Design treatment plans for patients with R/R B-ALL that optimize the current and future use of CD19 x CD3-targeting bispecific antibodies.

Please visit answersincme.com/860/240201307-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; and Dorothy Lo, MD, FRCP(C), MHSc, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patients with advanced urothelial carcinoma and resected/advanced RCC, with insights into regional practice considerations. Upon completion of this activity, participants should be better able to: Incorporate the latest evidence on frontline combination regimens into treatment planning for advanced urothelial carcinoma; Identify strategies to optimally incorporate adjuvant immunotherapy into treatment plans for eligible patients with early-stage renal cell carcinoma (RCC); and Evaluate how current evidence and guidelines may inform optimal sequencing of therapies in later-line settings for patients with advanced RCC.

Please visit answersincme.com/860/240201373-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Julie Stakiw, MD, FRCPC; and Constantine S. Tam, MBBS, MD. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss treatment management of high-risk CLL in both the frontline and relapsed/refractory settings. Upon completion of this activity, participants should be better able to: Identify high-risk chronic lymphocytic leukemia (CLL) based on cytogenetic, genomic, and clinical risk factors; Evaluate the latest clinical evidence informing the use of treatments for high-risk CLL in the frontline and relapsed/refractory (R/R) settings; and Apply guideline-concordant, evidence-based strategies to appropriately select and sequence treatments for high-risk CLL in the frontline and R/R settings.

Please visit answersincme.com/860/240201307-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; Krista Noonan, BSc, MD, FRCPC and Eleftherios Soleas, PhD In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patients with advanced urothelial carcinoma and resected/advanced RCC, with insights into regional practice considerations. Upon completion of this activity, participants should be better able to: Incorporate the latest evidence on frontline combination regimens into treatment planning for advanced urothelial carcinoma; Identify strategies to optimally incorporate adjuvant immunotherapy into treatment plans for eligible patients with early-stage renal cell carcinoma (RCC); and Evaluate how current evidence and guidelines may inform optimal sequencing of therapies in later-line settings for patients with advanced RCC.

Please visit answersincme.com/AZB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Salman R. Punekar, MD, MSc. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses the unmet treatment needs with current RAS(OFF) inhibitors and the potential role for emerging next-generation RAS(ON) inhibitors in KRAS-mutant NSCLC. Upon completion of this activity, participants should be better able to: Describe the persistent unmet needs in KRAS-mutant NSCLC, highlighting treatment gaps across diverse KRAS variants in pretreated advanced settings; Summarize the potential advantages of next-generation RAS(ON) inhibitors versus RAS(OFF) inhibitors; and Evaluate the future positioning of RAS(ON) inhibitors in clinical practice based on emerging evidence.

Please visit answersincme.com/KTB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Krina Patel, MD, MSc. In this activity, Krina Patel, MD, MSc, an expert in multiple myeloma, discusses emerging GPRC5D CAR T-cell therapies in relapse/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the clinical rationale for the use of emerging GPRC5D CAR T-cell therapy in the context of the current treatment landscape for relapsed/refractory multiple myeloma (RRMM); Review the implications of the latest clinical evidence for emerging GPRC5D CAR T-cell therapy in the treatment of patients with RRMM; and Outline potential considerations to optimally integrate GPRC5D CAR T-cell therapies, as they become available, into treatment plans for patients with RRMM.

Please visit answersincme.com/860/240201307-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Normand Blais, MD, MSc; Aly-Khan A. Lalani, MD, FRCPC; Wassim Kassouf, MD; and Eleftherios Soleas, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patients with advanced urothelial carcinoma and resected/advanced RCC, with insights into regional practice considerations. Upon completion of this activity, participants should be better able to: Incorporate the latest evidence on frontline combination regimens into treatment planning for advanced urothelial carcinoma; Identify strategies to optimally incorporate adjuvant immunotherapy into treatment plans for eligible patients with early-stage renal cell carcinoma (RCC); and Evaluate how current evidence and guidelines may inform optimal sequencing of therapies in later-line settings for patients with advanced RCC.

Please visit answersincme.com/FBF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Paolo Tarantino, MD, PhD and Christopher Vetter, MD, MSc, FACS. In this activity, experts in breast cancer discuss the role of neoadjuvant human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugates in HER2+ early-stage breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating the use of anti-HER2 ADCs for the neoadjuvant treatment of HER2-positive early-stage breast cancer; Review the clinical implications of the data for anti-HER2 ADCs in the neoadjuvant treatment of HER2-positive early-stage breast cancer; and Outline clinical, multidisciplinary considerations for the use of anti-HER2 ADCs in the neoadjuvant treatment of HER2-positive early-stage breast cancer.

Please visit answersincme.com/860/100850799-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Jane Meisel, MD, FASCO. In this activity, experts in breast cancer discuss practical approaches to optimize survivorship and patient care for patients with HER2-positive metastatic breast cancer who are on first-line maintenance treatment. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC.

Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC.

Please visit answersincme.com/860/101393625-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Yohann Loriot, MD, PhD and Andrea Necchi, MD. In this activity, experts in genitourinary cancers examine evidence-based strategies for integrating HER2 biomarker testing and HER2-directed antibody-drug conjugates into personalized, multidisciplinary care for advanced bladder cancer. Upon completion of this activity, participants should be better able to: Apply current guidelines to incorporate biomarker testing into treatment pathways for advanced bladder cancer; Evaluate emerging data on HER2-directed antibody-drug conjugates to guide the management of advanced bladder cancer; and Formulate multidisciplinary treatment plans to support personalized care for patients with HER2-positive advanced bladder cancer.

Please visit answersincme.com/860/100850799-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Sara A. Hurvitz, MD, FACP. In this activity, experts in breast cancer discuss the evolving standard-of-care and emerging first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the rationale for expanding the first-line maintenance therapy options for patients with HR-positive, HER2-positive mBC; and Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC.

Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alex Spira, MD, PhD, FASCO; and Kathryn C. Arbour, MD. In this activity "In this activity, experts in oncology discuss the evolving role of RAS(ON) inhibitors in shaping future treatment strategies for patients with KRAS-mutated non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Identify areas of unmet need in KRAS-mutant NSCLC across diverse KRAS variants in pretreated advanced settings; Describe the rationale for the use of RAS(ON) inhibitors for patients with KRAS-mutated NSCLC, based on evidence; and Assess how RAS(ON) inhibitors may be optimally used in clinical practice as they become available.

Please visit answersincme.com/860/97150451-replay4 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; Kristin Higgins, MD and Nicolas Girard, MD, PhD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss real-world learner questions to provide evidence-based strategies for applying immunotherapy in resectable and unresectable NSCLC, with practical guidance tailored to everyday clinical challenges. Upon completion of this activity, participants should be better able to: Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC; and Integrate patient-centered care into the management of early-stage NSCLC.

Please visit answersincme.com/860/97150451-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD and Kristin Higgins, MD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical steps for integrating consolidation immunotherapy in unresectable stage III NSCLC. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC; and Integrate patient-centered care into the management of early-stage NSCLC.

Please visit answersincme.com/JRV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lung cancer discusses the use of immunotherapy in clinical practice for patients with limited-stage (LS) and extended-stage (ES) small-cell lung cancer (SCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of immune checkpoint inhibitors in LS-SCLC and ES-SCLC; Assess the clinical profiles of approved and emerging immune checkpoint inhibitor therapies for LS-SCLC and ES-SCLC; and Outline evidence-based strategies for incorporating immune checkpoint inhibitor therapy into treatment plans for patients with LS-SCLC and ES-SCLC.

Please visit answersincme.com/FJJ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hematology and oncology discusses the use of noncovalent BTK inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) after at least 2 prior lines of therapy. Upon completion of this activity, participants should be better able to: Understand the rationale for noncovalent BTK inhibitors in relapsed/refractory (R/R) CLL/SLL after ≥2 prior lines of therapy; Evaluate the risk-benefit profiles of approved and emerging noncovalent BTK inhibitors in R/R CLL/SLL after ≥2 prior lines of therapy; and Develop patient-centered strategies with noncovalent BTK inhibitors to optimize outcomes in R/R CLL/SLL.

Please visit answersincme.com/860/97150451-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss treatment strategies for resectable and unresectable disease while highlighting ways to optimize long-term outcomes. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Integrate patient-centered care into the management of early-stage NSCLC.

Please visit answersincme.com/UNP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hepatology discusses the latest evidence and guideline recommendations for the first-line treatment of unresectable hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended preferred treatment options for management of unresectable HCC; and Recognize key clinical factors that should be considered when optimizing management for patients with unresectable HCC.

Please visit answersincme.com/860/IME-2025-21131-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hematology/oncology discuss use of anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM). Upon completion of this activity, participants should be better able to: Identify the rationale for anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM); Evaluate the clinical implications of evidence on anti-CD38 monoclonal antibody–containing quadruplet therapies in patients with NDMM; and Review strategies to optimize anti-CD38 monoclonal antibody–containing quadruplet therapies, including in the community setting.

Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimize outcomes in squamous disease. Upon completion of this activity, participants should be better able to: Assess guideline-based recommendations and biomarker profiles to inform first-line immunotherapy-based treatment selection for squamous NSCLC; Identify clinical factors that may be used to tailor first-line immunotherapy-based approaches across a range of PD-L1 expression levels and patient subtypes; and Recommend long-term, real-world clinical approaches to optimize the risk/benefit profiles of immunotherapy-based treatments in patients with squamous NSCLC.

Please visit answersincme.com/860/97150451-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss case-based strategies for integrating perioperative immunotherapy in resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC.

Please visit answersincme.com/XRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses how to optimize the use of adjuvant CDK4/6 inhibitors for managing patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. A patient also shares their experience with adjuvant CDK4/6 inhibitor therapy. Upon completion of this activity, participants should be better able to: Identify patients with hormone receptor–positive, HER2-negative, early breast cancer who are at a high risk of recurrence; Review current guidelines and evidence informing the use of adjuvant CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer; and Outline patient-centered strategies to optimize outcomes with adjuvant CDK4/6 inhibitors in hormone receptor–positive, HER2-negative, high-risk early breast cancer.

Please visit answersincme.com/ZWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer; Review the clinical profiles of TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer; and Apply guideline-concordant, evidence-based strategies to incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer.

Please visit answersincme.com/JXV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metastatic non–small-cell lung cancer discusses how to optimize frontline immunotherapy-based regimens for long-term outcomes. Upon completion of this activity, participants should be better able to: Identify patients with metastatic NSCLC who may benefit from first-line immunotherapy-based regimens; Evaluate the long-term evidence on first-line immunotherapy-based regimens for the treatment of patients with metastatic NSCLC; and Outline evidence-based, patient-centered strategies to ensure optimal use of first-line immunotherapy-based regimens, from initiation to follow-up care after discontinuation, in patients with metastatic NSCLC.

Please visit answersincme.com/BJV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses CD19-directed CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma. Upon completion of this activity, participants should be better able to: Review the rationale for CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; Discuss the clinical profiles of available CD19-directed CAR T-cell therapies for patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; and Outline patient-centered strategies for optimizing treatment with CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy.

Please visit answersincme.com/860/98336099-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss use of antibody-drug conjugates (ADCs) for patients with hormone-receptor (HR)–positive, HER2-low and -ultralow metastatic breast cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of HER2-low and ultralow status in patients with metastatic breast cancer (mBC); Integrate testing strategies for HER2-low and ultralow mBC; Evaluate the clinical data for antibody drug conjugates (ADCs) in HER2-low and ultralow mBC; and Propose practical strategies to enhance the current and future use of ADCs in HER2-low and -ultralow mBC.

Please visit answersincme.com/ZMN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses first-line treatment of advanced EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Review current guideline recommendations for the first-line treatment of advanced EGFR-mutated NSCLC; Describe the clinical implications of the latest evidence on first-line therapeutic strategies for advanced EGFR-mutated NSCLC; and Outline evidence-based strategies to personalize first-line therapeutic selection for patients with advanced EGFR-mutated NSCLC.

Please visit answersincme.com/860/240201301-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss how the latest evidence on frontline immunotherapy-based regimens can be integrated into practice to optimize outcomes for patients with advanced NSCLC. Upon completion of this activity, participants should be better able to: Review the latest data on frontline immunotherapy-based regimens for the treatment of advanced NSCLC; Identify patient-, disease-, and drug-related factors that may inform the frontline use of immunotherapy-based regimens for advanced NSCLC; and Outline evidence-based, multidisciplinary strategies to optimize long-term patient outcomes with frontline immunotherapy-based regimens in advanced NSCLC.

Please visit answersincme.com/860/99485655-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) use a case-based approach to explore evidence-based strategies to optimize early-stage, resectable NSCLC care with (neo)adjuvant/perioperative immunotherapy, highlighting the role of multidisciplinary teams. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the (neo)adjuvant/perioperative treatment of patients with early-stage, resectable NSCLC; Formulate strategies to appropriately integrate immunotherapy-based (neo)adjuvant/perioperative regimens into treatment plans for patients with early-stage, resectable NSCLC; Discuss multidisciplinary team approaches to enhance care for patients with early-stage, resectable NSCLC.

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.

Please visit answersincme.com/GTM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in sickle cell disease discusses comprehensive therapeutic selection strategies, from disease-modifying therapies to gene therapy options, and evidence-based approaches for optimizing patient outcomes across the disease spectrum. Upon completion of this activity, participants should be better able to: Review the impact that disease manifestations such as vaso-occlusive crises have on patients with sickle cell disease; Assess the efficacy and safety of available therapies for sickle cell disease and their implications for clinical practice; and Apply evidence-based strategies to optimize treatment outcomes in patients with severe sickle cell disease.

Please visit answersincme.com/860/240201294-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss how to select and sequence treatments for patients with CLL. Upon completion of this activity, participants should be better able to: Review guideline recommendations for preferred treatments in patients with CLL; Identify the clinical implications of the latest evidence informing the use of second-generation BTK inhibitors in patients with CLL; Outline practical strategies to optimize outcomes with second-generation BTK inhibitors in patients with CLL; and Describe emerging therapeutic agents currently under investigation for the treatment of CLL.

Please visit answersincme.com/FAH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancer discusses strategies to integrate anti-EGFR therapies into the treatment of metastatic colorectal cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of the latest evidence for anti-EGFR-based regimens for patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC); Outline strategies to optimize the integration of anti-EGFR-based regimens into management plans for patients with RAS/BRAF wild-type mCRC; and Review guideline recommendations for the management of RAS/BRAF wild-type mCRC.

Please visit answersincme.com/PYP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses TROP2-directed antibody-drug conjugates (ADCs) for the treatment of patients with advanced, pretreated EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Identify the rationale for using TROP2-directed ADCs in the treatment of patients with advanced, pretreated EGFR-mutated NSCLC; Review clinical evidence on emerging TROP2-directed ADCs in patients with advanced, pretreated EGFR-mutated NSCLC; and Outline evidence-based strategies to incorporate TROP2-directed ADCs for patients with advanced, pretreated EGFR-mutated NSCLC.

Please visit answersincme.com/BUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the latest treatments for transfusion-dependent beta thalassemia (TDT). Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the efficacy and safety data for novel TDT therapies; Identify appropriate patients for novel TDT therapies; and Apply strategies to integrate novel TDT therapies into real-world clinical practice.

Please visit answersincme.com/860/27391-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in breast cancer discuss patient-centered strategies to optimize quality of life by implementing a proactive approach to adverse event management for HR+, HER2- mBC. Upon completion of this activity, participants should be better able to: Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations; and Identify proactive, patient-focused strategies to elevate survivorship for patients receiving ADCs for HR+, HER2- mBC.

Please visit answersincme.com/860/27391-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts illustrate how to sequence available therapies for HR+, HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the expert recommendations regarding a sequential approach to the use of ADCs for HR+, HER2- metastatic breast cancer (mBC) management; and Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations.

Please visit answersincme.com/860/27391-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the available evidence informs sequencing strategies with antibody-drug conjugates for the optimization of care in HR+, HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the expert recommendations regarding a sequential approach to the use of ADCs for HR+, HER2- metastatic breast cancer (mBC) management; and Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations.

Please visit answersincme.com/RJB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in multiple myeloma discuss strategies for incorporating bispecific antibodies into the treatment of heavily pretreated relapsed/refractory multiple myeloma RRMM in the community setting. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of RRMM; Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated RRMM; Describe strategies to optimize outcomes with bispecific antibodies for the treatment of RRMM; and Outline practical considerations for incorporating bispecific antibodies into the treatment of heavily pretreated RRMM in the community setting. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MNK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss strategies for the use of novel tyrosine kinase inhibitors (TKIs) in the management of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using novel TKIs for newly diagnosed CP-CML; Discuss the clinical implications of the latest data for first-line novel TKIs in CP-CML; and Outline potential considerations to optimize outcomes for newly diagnosed patients with CP-CML on first-line TKIs.

Please visit answersincme.com/EYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses approved and emerging TROP2-directed ADCs for the treatment of HR-positive, HER2-negative/low advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for using TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced breast cancer; Discuss the clinical impact of approved and late-stage emerging TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer; and Outline guideline-concordant, evidence-based strategies to appropriately incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer.

Please visit answersincme.com/JUC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in obstetrics and gynecology and a cervical cancer survivor discuss strategies to increase human papillomavirus vaccination uptake, thereby reducing cervical cancer risk. Upon completion of this activity, participants should be better able to: Review guideline-recommended clinical strategies to reduce cervical cancer risk; Outline patient-focused strategies to increase acceptance of HPV vaccination across patient subpopulations; and Identify clinical approaches to enhance the uptake of recommended schedules for HPV vaccination.

Please visit answersincme.com/TBY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in colorectal cancer discuss management of patients with metastatic disease in the third line and beyond. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatments for patients with metastatic colorectal cancer (mCRC); Review the clinical implications of the latest evidence for later-line treatments for patients with mCRC; and Outline evidence-based approaches to improve long-term response rates in later-line treatment of mCRC.

Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemic approach to treatment; Review the clinical implications of the evidence on approved and emerging systemic therapies in patients with advanced BCC; and Describe practical strategies to optimize systemic treatment over the long term for patients with advanced BCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/ZVJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of metastatic colorectal cancer (mCRC) discusses treatment strategies to enhance patient outcomes during later-line therapy. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatments for patients with mCRC; Describe recent evidence for later-line treatments for patients with mCRC, including evidence informing treatment sequencing; and Review evidence-based, patient-centered approaches to manage adverse events for patients with mCRC receiving later-line treatment.

Please visit answersincme.com/HRY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the use of gene therapy for the treatment of sickle cell disease (SCD). Upon completion of this activity, participants should be better able to: Identify the rationale for the use of gene therapy in sickle cell disease; Review the clinical significance of the latest trial data for gene therapy in sickle cell disease; and Outline considerations to optimize the use of gene therapy in patients with sickle cell disease.